

promoting access to White Rose research papers



Universities of Leeds, Sheffield and York
<http://eprints.whiterose.ac.uk/>

This is the Author's Accepted version of an article published in the **European Heart Journal**

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/id/eprint/78302>

Published article:

West, RM, Cattle, BA, Bouyssie, M, Squire, I, de Belder, M, Fox, KA, Boyle, R, McLenachan, JM, Batin, PD, Greenwood, DC and Gale, CP (2011) *Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales*. *European Heart Journal*, 32 (6). 706 - 711. ISSN 0195-668X

<http://dx.doi.org/10.1093/eurheartj/ehq476>

Title Impact of hospital proportion and volume on primary PCI performance in England and Wales.

Authors RM West¹ BA Cattle¹ M Bouyssie^{1,2}, I Squire³, M DeBelder⁴, KAA Fox⁵, R Boyle⁶, JM McLenachan⁷, PD Batin⁸, DC Greenwood¹, CP Gale^{1,9}

¹Division of Biostatistics, University of Leeds, Leeds, UK.

²Université Paul Sabatier, Toulouse, France.

³Department of Cardiovascular Sciences, University of Leicester, UK

⁴Department of Cardiology, South Tees NHS Trust, UK

⁵Centre for Cardiovascular Science, University of Edinburgh, UK.

⁶Department of Health, London, UK.

⁷Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

⁸Department of Cardiology, Mid-Yorkshire NHS Trust, Wakefield, UK.

⁹Department of Cardiology, York Hospitals NHS Foundation Trust, York, UK

Correspondence Chris P. Gale

BSc (Hon), MBBS, MRCP, PhD, Dip, M.Ed.

National Institute for Health Research Clinician Scientist* and Honorary Consultant
Cardiologist^

*Division of Biostatistics, Level 8, Worsley building, University of Leeds, Clarendon
Way, West Yorkshire, Leeds, LS2 9JT, UK

^ York Hospital, Wigginton Road, York, YO31 8HE, UK

c.p.gale@leeds.ac.uk, Tel: +44(0) 113 343 4890, Fax: +44(0) 113 343 4877

Ethical approval Ethical approval was not required.

Details of funding MINAP is funded by the Healthcare Commission
This study was funded by the British Heart Foundation
CPG is funded by the National Institute for Health
Research

Conflicts of interest There were no conflicts of interest

Word count: 2,708 (excluding abstract and references)

Abstract: 245

References: 51

Tables: 3

Figures: 5

Abstract

Aims: To quantify the determinants of primary PCI performance in England and Wales between 2004 and 2007.

Methods and results: All 8,653 primary PCI cases admitted to acute hospitals in England and Wales as recorded in the Myocardial Ischaemia National Audit Project (MINAP) 2004–7. We studied the impact of the volume of primary PCI cases (hospital volume) on DTB times and the proportion of patients treated with primary PCI (hospital proportion) on 30-day mortality and employed regression analysis to identify reasons for DTB time variations with a multilevel component to express hospital variation. The proportion of patients receiving pPCI increased from 5% in 2004 to 20% in 2007. Median DTB times reduced from 84 minutes in 2004 to 61 minutes in 2007. Median DTB times decreased as the number of pPCI procedures increased. The 30-day all cause mortality rate, 95% CI for hospitals that performed pPCI for less than 25% of STEMI patients was significantly higher than those that performed pPCI for greater than 75% (5.0%, 3.9% to 6.1% versus 2.7%, 2.0% to 3.5%). Time-of-day, year of admission, sex and diabetes significantly influenced DTB times. Hospital variation was evident by a hospital-level DTB time standard deviation of 12 minutes.

Conclusions: There was large variation in DTB times between the best and worst performing hospitals. Although patient-related factors impact upon DTB times, volume and proportion of patients undergoing primary PCI significantly influence

delay and early mortality - hospitals with the highest proportion of primary PCI had the lowest mortality.

Key words: Primary PCI; STEMI; door-to-balloon time; mortality; hospital volume; hospital proportion.

Introduction

The benefits of primary PCI diminish if there are delays to revascularisation of the infarct-related artery¹⁻⁴; longer revascularisation times are associated with increased in-hospital mortality⁵⁻⁷. Hospital-level influences account for up to a third of the ‘total ischaemic time’ and incorporate many factors, including the availability of a skilled catheterisation laboratory team (specialist centre effect); the number of patients treated (hospital volume effect) and patient-level factors⁷⁻¹⁵.

Earlier studies revealed that lower volume primary PCI centers conferred elevated mortality^{9,11,15,17}. Recently, however, this has been debated^{12,17} with evidence from the National Registry of Myocardial Infarction to suggest that a greater level of hospital ‘specialisation’ was associated with reduced in-hospital mortality¹². Indeed, integrated systems of care that redirect ST-elevation myocardial infarction (STEMI) patients to higher volume, higher ‘specialisation’ interventional centres (where greater proportions of STEMI cases undergo primary PCI) may offer improved outcomes beyond the length of the hospital admission. Currently such ‘Heart Attack Centers’ do not exist in England and Wales although there is a strategy to provide a national primary PCI service for STEMI, by 2012¹⁸. This study therefore aimed to quantify the determinants of primary PCI performance for STEMI patients in England and Wales during the period 2004–2007, and to investigate the impact of hospital reperfusion strategies on primary PCI performance.

Methods

Study design

The analyses were based on data from the Myocardial Ischaemia National Audit Project (MINAP) whose national database was established in 1999 to examine the quality of management of acute myocardial infarction in England and Wales and to meet the audit requirements of the National Service Framework for coronary heart disease¹⁹. MINAP has been long established as a vehicle for evaluating service provision especially regarding call-to-needle (CTN) and door-to-needle (DTN) times for thrombolysis²⁰⁻²². This clinical database collects patient data from all acute hospitals in England and Wales²³⁻²⁵.

Data for patients admitted with an acute coronary syndrome (ACS) are collected prospectively at each acute hospital by a secure electronic system, developed by the Central Cardiac Audit Database (CCAD), electronically encrypted and transferred on-line to a central database²⁶. CCAD is part of the National Clinical Audit Support Programme (NCASP)²⁷ which is part of the National Health Service (NHS) Information Centre for Health and Social Care²⁸. MINAP is overseen by a multi professional steering group representing the stakeholders and is based at the National Institute for Clinical Outcomes Research (NICOR) at University College London²³.

Each patient entry offers details of the patient journey, including the method and timing of admission, in-patient investigations, treatment, and date of all cause death

(from linkage to the UK Statistics Authority using a unique NHS number). Data entry is subject to routine on-line error checking. There is a mandatory annual data validation exercise for each hospital²⁰.

Analogous to the annual national audit of thrombolysis times²⁰, primary PCI performance is evaluated using times to reperfusion. In 2009, the call to balloon (CTB) time was adopted by the NHS Information Centre for Health and Social Care as a new indicator of quality improvement for acute care²⁹. Our study specifically focuses on hospital performance and therefore analyses are based upon the door to balloon time (DTB), akin to the door-to-needle time for thrombolysis. The DTB time is a hospital-based performance indicator^{30,31} and is defined as the difference between the time of arrival of the ambulance to the first hospital and the time of first balloon inflation (the accident and emergency time is taken if the patient self presents to hospital).

Cohort description

The MINAP cohort comprised 324,083 independent ACS events admitted to acute hospitals in England and Wales between 1st January 2004 and 31st December 2007. Of these, there were 71,995 patients with an initial diagnosis of STEMI.

Statistical methods

The population was described by unadjusted numbers, percentages with 95% confidence intervals with respect to discrete data, and by medians and interquartile range or mean ± 1.96 SD for continuous variables. Pearson's chi-squared test was used to determine whether there was a significant difference between the expected

frequencies and the observed frequencies in one or more categories. The Mann–Whitney U test was used to assess whether two independent samples arose from the same distribution. The time of admission was divided into ‘day’ and ‘night’ with day defined as 08:00 until 20:00. Temporal data were smoothed using a LOESS algorithm

32.

To account for variations at the hospital level, a linear mixed-effects regression model was used to model the relationship between DTB times and age, year of admission, time-of-arrival (day or night), diabetic status, hospital proportion of cases, and Index of Multiple Deprivation (IMD) score. The IMD score combines information on income, employment, health deprivation and disability, education skills and training, housing, geographical access to services, and living environment for areas containing a minimum of 1,000 people and 400 households. The primary PCI proportion per hospital was defined as the number of patients with an admission diagnosis of STEMI who underwent primary PCI divided by the global number of cases with an admission diagnosis of STEMI for that hospital. The selection of covariates for the model was based upon those that were clinically and statistically significant. Hospitals with less than 10 primary PCI cases were excluded²⁹. Of the STEMI cohort, 5.6% had missing data for 30-day mortality. The DTB times were 85% complete.

Results

There were 8,653 (12%) patients who underwent primary PCI. The mean age for the primary PCI cohort was 62.9 years (95% confidence interval: 62.8 years to 63.1 years), 74.1% were male and 13.9% had diabetes. The mean (95% confidence interval) systolic BP and heart rate on admission was 136.7 mmHg (79.8 mmHg to 193.6 mmHg) and 77.0 bpm (37.4 bpm to 116.6 bpm) respectively. The baseline characteristics for the cohort are presented by year in Table 1.

30-day mortality

The unadjusted all-cause 30-day mortality for primary PCI was 4.1% (95% confidence interval: 3.7% to 4.6%). Primary PCI 30-day mortality rates fell, reaching 3.3% (95% confidence interval: 2.7% to 4.1%) in 2007 from 5.3% (95% confidence interval: 3.6% to 7.0%) in 2004.

Year and time of admission

The total number of treated STEMI cases fell from 19,757 in 2004 to 15,573 in 2007. The rate of introduction of the primary PCI service is presented in Figure 1. In 2005 5% of STEMI cases were treated using primary PCI (n = 915) compared with 9% (n = 1,744) in 2005, 16% (n = 2,853) in 2006, and 20% (n = 3,141) in 2007 (Chi-squared for trend = 2348.59, df = 3, $P < 0.001$). Over the 4 years the total rates of reperfusion for STEMI (thrombolysis and primary PCI) remained constant at approximately 70%. Two thirds of patients who underwent primary PCI (66%) were treated between 08:00 and 20:00.

Hospital volume and proportion effect

Figure 2 shows that there was a significant difference in the 30-day all cause mortality rate, 95% CI for those hospitals that performed primary PCI for fewer than 25% of STEMI patients compared to more than 75% (5.0%, 3.9% to 6.1% versus 2.7%, 2.0% to 3.5%). There was no significant relationship between the number of primary PCI cases undertaken (hospital volume) and 30-day all cause mortality. However, higher volume centres had shorter DTB times (Figure 3).

Reperfusion times

The median DTB time for males was 8 minutes shorter than for females (Table 2). The median DTB time for patients with diabetes was 71 minutes (interquartile range 66 minutes), whereas for patients without diabetes the median DTB time was 67 minutes (interquartile range 58 minutes).

Figure 4 demonstrates significant diurnal variation in DTB times over 24 hours – with evidence for nocturnal peaks and daytime troughs. The longest DTB times occurred at approximately 08:00, whilst the shorter DTB times occurred between 09:00 and 20:00.

There was a year-on-year decrease in the DTB times (Figure 5). In 2004 the median DTB time was 84 minutes and 56% of patients were reperfused within 90 minutes. By 2007 the median time reduced by 23 minutes to 61 minutes and a further 20% (total 76%) of patients were reperfused within 90 minutes.

Modelling the DTB time

The DTB times by night were 11 minutes longer than those by day (Table 3). Females and those with diabetes had DTB times 3.5 minutes greater than males and patients without diabetes. Each year an improvement in DTB times was observed. Hospitals that performed primary PCI on greater than 75% of STEMIs had DTB times 30 minutes shorter than hospitals which performed PCI on less than 75% of STEMIs: the *hospital-proportion effect*.

Younger patients had shorter DTB times than older patients. For example, a 40 year patient would, on average have a DTB time 4 minutes shorter than an 80 year old patient. Patients with higher IMD scores (more deprived) are predicted to have longer DTB times than those with lower IMD scores. The *hospital effect* for DTB times (after accounting for the hospital proportion effect.) was predicted to be 51 minutes between the best and worst performing hospitals. The residual variation in DTB times was greater at the patient-level (SD = 32.7 minutes) than at the hospital-level (SD = 12.1 minutes).

Discussion

This study identifies several important details relating to variations in DTB times and early mortality: namely the *time-of-day effect*; the *hospital effect*, the *hospital volume effect* and the *hospital-proportion effect*, and are in keeping with findings from other registries^{9,10,12,14,16,33-35}. In particular, it readily shows that 1) high volume centres have lower DTB times, 2) there is a statistically significant difference in mortality rates between those hospitals that perform primary PCI on over 75% of STEMI patients compared with less than 25% (2.7% versus 5.0% respectively), and that 3) high volume centres do not have lower mortality rates than low volume centres. This study therefore demonstrates that of the analyses, it is the proportion rather than volume of primary PCIs undertaken that is more relevant to improved primary PCI performance at the hospital level¹⁷.

The multilevel analysis splits the variation in DTB times into components associated with the patient and with the hospital. Increasing age, female sex and diabetes are associated with small but statistically significant longer DTB times. In contrast, the individual hospital effects are much larger – they clearly demonstrate that it does matter at which hospital a patient is admitted – there is a statistically and clinically significant delay at some hospitals, the best being almost an hour faster than the slowest. The service in many hospitals in England and Wales, however, is evolving: DTB times and 30-day mortality rates overall have decreased as the service has evolved so that the variation between hospitals may be due solely to the different degrees with which primary PCI has become an established treatment option.

We report a significant year-on-year reduction in the number of STEMI cases and a trend towards reduced annual 30-day mortality rates from primary PCI. The reduction in rates of STEMI is consistent with previously reported registries³⁶. Patient characteristics including cardiogenic shock, diabetes, previous myocardial infarction, angina, chronic renal failure and hypertension (see Table 1) did not vary considerably between 2004 and 2007 and are therefore unlikely to explain the reduction in mortality rates. Instead, increased 30-day mortality was associated with hospitals that performed primary PCI on a low proportion of STEMI patients. This study builds on the notion that hospitals with high levels of ‘specialisation’ are associated with lower mortality rates¹² to show that the *hospital proportion effect* extends beyond the length of the hospital admission to 30 days. It is likely that a statistically significant reduction in mortality was not evident between 2004 and 2007 because there was little change in the proportion of hospitals performing primary PCI on less than 50% of STEMI cases. We speculate that an increase in the numbers of centres performing primary PCI on over 75% of STEMI cases would offer greater reductions in 30-day mortality rates. Indeed, analysis of the National Registry of Myocardial Infarction-4 has revealed that a 36% relative risk reduction in in-hospital mortality was evident for centres performing primary PCI on over 88.5% of STEMI cases compared to those performing it on less than 34.0%¹².

Those hospitals that perform primary PCI on over 75% of STEMIs are very likely to offer a 24-hour primary PCI service. When a 24-hour primary PCI service is provided, it is apparent that DTB times are longer at night - consistent with the healthcare team being called in for the procedure – at the time of analysis there were no primary PCI centres in England and Wales which had a policy whereby the

primary PCI team and first operator were resident in the hospital. Furthermore, the increase in DTB times between 07:00 and 09:00 is likely to be due to a decision to wait until the primary PCI team was available⁸. With evidence to suggest that delays to reperfusion are associated with higher mortality rates^{1,5,7}, this might be investigated in more detail at specific hospitals and raises the issue of the decision to thrombolysate should primary PCI only be available after a delay^{6,37,38}. An alternative model of care would be large volume, high proportion 'heart attack centres' with 1) a 24 hour primary PCI service, 2) dedicated primary PCI catheter labs, and 3) a primary PCI team (including the first operator) resident in the hospital.

Whilst there is evidence to suggest that two-thirds of the delay to revascularisation occurs before first medical contact (patient delay)³⁹, there remains a substantial opportunity for improvement at the hospital level: for example, over the 4 years studied, there was no appreciable decrease in the number of patients with STEMI not reperfused. This is surprising when primary PCI has fewer contra-indications than thrombolysis⁴⁰. We clearly identify hospital characteristics (high volume) which are associated with reduced DTB times and a model of delivery of care (high proportion) associated with reduced early 30-day mortality. Consequently, this research brings to light the necessity for consideration of high throughput "Heart Attack Centres" and provides additional evidence to support the need for strategic networks of care⁴⁶.

Limitations

MINAP does not collect data on all ACS patients in England and Wales and it is possible that patients entered into the MINAP database differ from those not recorded. We noted that the recording of DTB times was 85% complete and the resulting bias due to missing data could potentially be large⁴⁷. Between 2004 and 2007, the emergency management of STEMI in England and Wales differed from that of other countries - the primary PCI rate in other health care systems at a similar period in time was higher^{40,48,49}. Nonetheless England and Wales compared favorably with data from North America, where in 2004 the median DTB time was reported as 100.4 ± 23 minutes⁵⁰. The modelling of DTB times was limited to 9 key variables and this may have not considered other determinants of DTB times. Hospital performance may have changed recently as this study only considers data to the end of 2007²⁰. Finally, this research reveals important associations but cannot prove cause and effect.

Conclusions

Several primary PCI hospital process-related factors have been identified: namely the *time-of-day effect*; the *hospital effect* and the *hospital-proportion effect*. These are central to the development and evaluation of a national primary PCI service. In addition to patient related factors that impact upon DTB times, volume and proportion of patients treated with primary PCI influence delay and early mortality. This paper provides evidence to support the concept of 'Heart Attack Centres' where high throughput primary PCI offers improved patient care.

Acknowledgements

All of the authors gratefully acknowledge funding from the British Heart Foundation PG/07/057/23215. CG is funded through the National Institute for Health Research (NIHR). The extract from the MINAP database was provided through the MINAP Academic Group. We acknowledge all the hospitals in England and Wales for their contribution of data to MINAP. There are no competing interests and the authors have nothing to declare.

Table 1. Baseline characteristics for the primary PCI cohort.

	2004	2005	2006	2007
Number of primary PCI cases	915	1744	2853	3141
Demographics				
Mean (SD) age, years	62.2 (12.8)	62.5 (12.8)	63.1 (13.5)	63.2 (12.9)
Male sex (%)	674 (73.7)	1316 (75.5)	2089 (73.2)	2304 (73.3)
Median (IQR) IMD score*	25.8 (28.3)	23.5 (25.8)	21.1 (25.1)	20.2 (25.3)
Cardiovascular risk factors				
Previous myocardial infarction (%)	131 (14.3)	212 (12.2)	354 (12.4)	404 (12.9)
Previous angina (%)	130 (14.2)	249 (14.3)	407 (14.3)	401 (12.8)
Hypertension (%)	355 (38.8)	683 (39.2)	1153 (40.4)	1154 (36.7)
Diabetes (%)	116 (12.7)	221 (12.7)	371 (13.0)	402 (12.7)
Current smoker (%)	419 (45.8)	693 (39.7)	1040 (36.4)	1161 (37.0)
Chronic renal failure (%)	20 (2.2)	25 (1.4)	46 (1.6)	56 (1.8)
Haemodynamic characteristics				
Mean (SD) systolic BP, mmHg	136.2 (28.7)	137.1 (28.4)	137.1 (29.8)	136.2 (29.6)
Mean (SD) heart rate, bpm	75.7 (21.2)	76.8 (19.7)	77.3 (20.3)	77.2 (20.1)
Cardiogenic shock (%)	22 (2.4)	37 (2.1)	81 (2.8)	102 (3.2)
Reperfusion times				
Median (IQR) CTB time, minutes	133 (85)	128 (61)	117 (54)	112 (49)
Median (IQR) DTB time, minutes	84 (60)	77 (66)	65 (61)	61 (63)
Treatments				
Aspirin on admission (%)	728 (79.6)	1457 (83.5)	2311 (81.0)	2785 (88.7)
Aspirin on discharge (%)	736 (80.4)	1248 (71.6)	2238 (78.4)	2679 (85.3)
Clopidogrel on discharge (%)	81 (8.8)	634 (36.3)	1737 (60.8)	2253 (71.2)
Statin on discharge (%)	731 (79.9)	1262 (72.4)	2219 (77.8)	2674 (85.1)
β blocker on discharge (%)	640 (69.9)	1096 (62.8)	1918 (67.2)	2341 (74.5)
ACE inhibitor on discharge (%)	682 (74.5)	1176 (67.4)	2045 (71.7)	2489 (79.2)

*Index of Multiple Deprivation, higher scores signify greater deprivation.

CTB: call to balloon; DTB: door to balloon




Figure 1. Primary PCI and thrombolysis rates adjusted for STEMI admission rate.




Figure 2: 30-day mortality rate by proportion of STEMI cases treated by primary PCI.




Figure 3: Median door to balloon time (minutes) by hospital volume and proportion of primary PCI cases.

Table 2: Median and interquartile range (IQR) of DTB times by sex and diabetic status.

Characteristic		Median (IQR) DTB time, minutes	Level of significance
Sex	Male	65 (57)	$P < 0.001$
	Female	73 (62)	
Diabetes	Yes	71 (66)	$P = 0.03$
	No	67 (58)	




Figure 4: Diurnal variation in DTB times.




Figure 5: Box-plot of DTB times by year of admission.

Table 3: Modelling of DTB times to show the impact of confounding variables.

	Estimate (95% confidence interval), minutes
Fixed effects:	
Intercept [^]	85.2 (79.9 to 90.4)
Arrival at night	11.5 (9.3 to 13.7)
Year 2005	-6.0 (-9.3 to -2.8)
Year 2006	-12.0 (-15.1 to -8.9)
Year 2007	-18.4 (-22.1 to -14.7)
Female	3.5 (1.1 to 5.8)
Diabetes	3.9 (1.0 to 6.8)
Age (by 1 year)	0.1 (0 to 0.2)
Hospital proportion >75%	-29.9 (-42.2 to -17.7)
IMD score*	0.1 (0.1 to 0.2)
Random effects:	
Hospital standard deviation	12.1 (9.2 to 16.0)
Patient level standard deviation	32.7 (32.0 to 33.4)

[^]The reference group time is for a 63 year-old male without diabetes admitted in 2004 to a hospital with a primary PCI rate of less than 75% and living in area with an IMD score of 20.

*Index of Multiple Deprivation.

Reference List

1. Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, Krumholz HM, for the National Cardiovascular Data Registry. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. *BMJ* 2009;**338**(may19_1):b1807.
2. Terkelsen CJ, Christiansen EH, Sorensen JT, Kristensen SD, Lassen JF, Thuesen L, Andersen HR, Vach W, Nielsen TT. Primary PCI as the preferred reperfusion therapy in STEMI: it is a matter of time. *Heart* 2009;**95**(5):362-369.
3. Nallamothu B, Fox KA, Kennelly BM, Van de WF, Gore JM, Steg PG, Granger CB, Dabbous OH, Kline-Rogers E, Eagle KA. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. *Heart* 2007.
4. De LG, Suryapranata H, Zijlstra F, van 't Hof AW, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. *J Am Coll Cardiol* 2003;**42**(6):991-997.
5. McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, Peterson ED, Blaney M, Frederick PD, Krumholz HM. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2006;**47**(11):2180-2186.
6. Tarantini G, Razzolini R, Napodano M, Bilato C, Ramondo A, Iliceto S. Acceptable reperfusion delay to prefer primary angioplasty over fibrin-specific thrombolytic therapy is affected (mainly) by the patient's mortality risk: 1 h does not fit all. *Eur Heart J* 2010;**31**(6):676-683.
7. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Jr., Antman EM, Cannon CP, Gibson CM. Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction: Implications When Selecting a Reperfusion Strategy. *Circulation* 2006;**114**(19):2019-2025.
8. Huber K, Goldstein P, Danchin N, Fox KAA. Network models for large cities: the European experience. *Heart* 2010;**96**(2):164-169.
9. Magid DJ, Calonge BN, Rumsfeld JS, Canto JG, Frederick PD, Every NR, Barron HV, for the National Registry of Myocardial Infarction. Relation Between Hospital Primary Angioplasty Volume and Mortality for Patients With Acute MI Treated With Primary Angioplasty vs Thrombolytic Therapy. *JAMA: The Journal Of The American Medical Association* 2000;**284**(24):3131-3138.
10. Canto JG, Every NR, Magid DJ, Rogers WJ, Malmgren JA, Frederick PD, French WJ, Tiefenbrunn AJ, Misra VK, Kiefe CI, Barron HV. The volume of primary angioplasty procedures and survival after acute myocardial infarction.

National Registry of Myocardial Infarction 2 Investigators. *N Engl J Med* 2000;**342**(21):1573-1580.

11. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, . A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1993;**328**(10):673-679.
12. Nallamothu BK, Wang Y, Magid DJ, McNamara RL, Herrin J, Bradley EH, Bates ER, Pollack CV, Jr., Krumholz HM. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis. *Circulation* 2006;**113**(2):222-229.
13. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. *Circulation* 2003;**108**(15):1809-1814.
14. Spaulding C, Morice MC, Lancelin B, El HS, Lepage E, Bataille S, Tresca JP, Mouranche X, Fosse S, Monchi M, de VN. Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry. *Eur Heart J* 2006;**27**(9):1054-1060.
15. Terkelsen CJ, Lassen JF. Treatment delays in ST elevation myocardial infarction. *BMJ* 2008;**336**(7641):401-402.
16. Tsuchihashi M, Tsutsui H, Tada H, Shihara M, Takeshita A, Kono S. Volume-outcome relation for hospitals performing angioplasty for acute myocardial infarction: results from the Nationwide Japanese Registry. *Circ J* 2004;**68**(10):887-891.
17. Kumbhani DJ, Cannon CP, Fonarow GC, Liang L, Askari AT, Peacock WF, Peterson ED, Bhatt DL, for the Get With the Guidelines Steering Committee and Investigators. Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes. *JAMA: The Journal Of The American Medical Association* 2009;**302**(20):2207-2213.
18. DH Vascular Programme Team. Treatment of Heart Attack National Guidance. Final Report of the National Infarct Angioplasty Project (NIAP). Department of Health. 2008.
19. Department of Health (2000) National Service Framework for coronary Heart Disease. The Stationary Office, London.
20. How the NHS manages heart attacks. Eighth public report 2009t. National Institute for Clinical Outcomes Research, London 2009.
21. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF. Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP). *Heart* 2004;**90**(9):1004-1009.

22. Birkhead JS. Trends in the provision of thrombolytic treatment between 1993 and 1997. Myocardial Infarction Audit Group. *Heart* 1999;**82**(4):438-442.
23. http://www.rcplondon.ac.uk/college/ceeu/ceeu_ami_home.htm. Accessed February 2010.
24. Birkhead J, Walker L. National audit of myocardial infarction (MINAP): a project in evolution. *Hosp Med* 2004;**65**(8):452-453.
25. Birkhead JS. Responding to the requirements of the national service framework for coronary disease: a core data set for myocardial infarction. *Heart* 2000;**84**(2):116-117.
26. Rickards A, Cunningham D. From quantity to quality: the central cardiac audit database project. *Heart* 1999;**82**(90002):18ii-22.
27. <http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp>. Accessed February 2010. 2010.
28. <http://www.ic.nhs.uk/>. Accessed February 2010. 2010.
29. <https://mqi.ic.nhs.uk/IndicatorDefaultView.aspx?ref=1.01.01>. Accessed September 2009. 2009.
30. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, Ho PM, Kosiborod MN, Masoudi FA, Nallamothu BK. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. *J Am Coll Cardiol* 2008;**52**(24):2046-2099.
31. Tu JV, Khalid L, Donovan LR, Ko DT. Indicators of quality of care for patients with acute myocardial infarction. *CMAJ* 2008;**179**(9):909-915.
32. de Boor C. A practical guide to splines. Springer-Verlag. 1978.
33. Magid DJ, Wang Y, Herrin J, McNamara RL, Bradley EH, Curtis JP, Pollack CV, Jr., French WJ, Blaney ME, Krumholz HM. Relationship Between Time of Day, Day of Week, Timeliness of Reperfusion, and In-Hospital Mortality for Patients With Acute ST-Segment Elevation Myocardial Infarction. *JAMA: The Journal Of The American Medical Association* 2005;**294**(7):803-812.
34. Cubeddu RJ, Cruz-Gonzalez I, Kiernan TJ, Truong QA, Rosenfield K, Leinbach RC, Cadigan ME, Pomerantsev EV, Palacios IF. ST-elevation myocardial infarction mortality in a major academic center "on-" versus "off-" hours. *J Invasive Cardiol* 2009;**21**(10):518-523.

35. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. *N Engl J Med* 2007;**357**(16):1631-1638.
36. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, Pollack Jr CV, Gore JM, Chandra-Strobos N, Peterson ED, French WJ. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *American Heart Journal* 2008;**156**(6):1026-1034.
37. Van de WF, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di MC, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 2008;**29**(23):2909-2945.
38. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? *Am J Cardiol* 2003;**92**(7):824-826.
39. Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf F, Lopez-Sendon J, Goodman SG, Quill A, Fox KAA, for the Global Registry of Acute Coronary Events (GRACE) Investigators. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. *European Heart Journal* 2008;**29**(5):609-617.
40. Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a treatment of the past? *Circulation* 2003;**107**(20):2538-2542.
41. Fox KA, Huber K. A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it? *Nat Clin Pract Cardiovasc Med* 2008;**5**(11):708-714.
42. Knot J, Widimsky P, Wijns W, Stenestrand U, Kristensen SD, Van' TH, Weidinger F, Janzon M, Norgaard BL, Soerensen JT, van de WH, Thygesen K, Bergsten PA, Digerfeldt C, Potgieter A, Tomer N, Fajadet J. How to set up an effective national primary angioplasty network: lessons learned from five European countries. *EuroIntervention* 2009;**5**(3):299, 301-299, 309.
43. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, Lips DL, Madison JD, Menssen KM, Mooney MR, Newell MC, Pedersen WR, Poulouse AK, Traverse JH, Unger BT, Wang YL, Larson DM. A Regional System to Provide Timely Access to Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. *Circulation* 2007;**116**(7):721-728.

44. Holmes DR, Jr., Bell MR, Gersh BJ, Rihal CS, Haro LH, Bjerke CM, Lennon RJ, Lim CC, Ting HH. Systems of care to improve timeliness of reperfusion therapy for ST-segment elevation myocardial infarction during off hours: the Mayo Clinic STEMI protocol. *JACC Cardiovasc Interv* 2008;**1**(1):88-96.
45. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, Andrikopoulos G, Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne P, Hartikainen J, Huber K, Kala P, Klin-ïeva M, Kristensen SD, Ludman P, Ferre JM, Merkely B, Mili-ii-ç D, Morais J, No-ì M, Opolski G, Ostoji-ç M, Radovanovi-ì D, de Servi S, Stenestrand U, Studen-ian M, Tubaro M, Vasiljevi-ç Z, Weidinger F, Witkowski A, Zeymer U. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. *European Heart Journal* 2010;**31**(8):943-957.
46. McCullag P, Nelder JA. Generalized Linear Models, 2nd ed. London: Chapman & Hall. 1989.
47. Cattle BA, Greenwood DC, Gale CP, West RM. Ups and downs of balloon times. *BMJ* 2009;**338**(jun15_1):b2424.
48. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A, Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S, on behalf of the Euro Heart Survey Investigators. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. *European Heart Journal* 2006;**27**(19):2285-2293.
49. Widimsky P, Wijns W, Fajadet J, de BM, Knot J, Aaberge L, Andrikopoulos G, Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne P, Hartikainen J, Huber K, Kala P, Klineva M, Kristensen SD, Ludman P, Ferre JM, Merkely B, Milicic D, Morais J, Noc M, Opolski G, Ostojic M, Radovanovic D, De SS, Stenestrand U, Studencan M, Tubaro M, Vasiljevic Z, Weidinger F, Witkowski A, Zeymer U. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. *Eur Heart J* 2010;**31**(8):943-957.
50. Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb JM, Krumholz HM. Strategies for reducing the door-to-balloon time in acute myocardial infarction. *N Engl J Med* 2006;**355**(22):2308-2320.